Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort

Acta Neuropathologica

Volumn 128, Issue 1, 2014, Pages 137-149

  Pietsch, Torsten ^a   Schmidt, Rene ^b   Remke, Marc ^d   Korshunov, Andrey ^c,e   Hovestadt, Volker ^c   Jones, David T W ^c   Felsberg, Jörg ^c,f   Kaulich, Kerstin ^c,f   Goschzik, Tobias ^a   Kool, Marcel ^c   Northcott, Paul A ^c   Von Hoff, Katja ^g   Von Bueren, André O ^g,h   Friedrich, Carsten ^g   Mynarek, Martin ^g   Skladny, Heyko ⁱ   Fleischhack, Gudrun ^j   Taylor, Michael D ^d   Cremer, Friedrich ⁱ   Lichter, Peter ^c   Faldum, Andreas ^b   Reifenberger, Guido ^c,f   Rutkowski, Stefan ^g   Pfister, Stefan M ^c,k   more..

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

ⁱ Centre for Human Genetics   (Germany)

^j UNIVERSITY OF DUISBURG ESSEN   (Germany)

^k UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

more..

Author keywords

Biomarker; Clinical trial cohort; Medulloblastoma; Methylation profiling; Prospective; Risk stratification

Indexed keywords

BETA CATENIN; CTNNB1 PROTEIN; MYC PROTEIN; SYNAPTOPHYSIN; TUMOR MARKER; UNCLASSIFIED DRUG; WNT PROTEIN; BIOLOGICAL MARKER; CTNNB1 PROTEIN, HUMAN; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; SYP PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CANCER PROGNOSIS; CELL COMPONENT; CELL PROLIFERATION; CEREBROSPINAL FLUID CYTOLOGY; CHILD; CHROMOSOME 17; CHROMOSOME 6Q; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; ENDOTHELIUM CELL; EPENDYMOBLASTOMA; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MULTICENTER STUDY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUTATIONAL ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; TUMOR DIAGNOSIS; BRAIN NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; GENETICS; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; RISK; YOUNG ADULT;

ADOLESCENT; ADULT; BETA CATENIN; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DNA METHYLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; MEDULLOBLASTOMA; NEOPLASM STAGING; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; PROSPECTIVE STUDIES; RISK; SYNAPTOPHYSIN; YOUNG ADULT;

EID: 84903817160     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-014-1276-0     Document Type: Article

References (33)

1. Cho Y-J, Tsherniak A, Tamayo P et al (2011) Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 29(11):1424-1430. doi:10.1200/jco.2010.28.5148
2. Clifford S, Lusher M, Lindsey J et al (2006) Wnt/wingless pathway activation and chromosome 6 loss characterise a distinct molecular sub-group of medulloblastomas associated with a favourable prognosis. Cell Cycle 5(22):2666-2670
3. Dahmen RP, Koch A, Denkhaus D et al (2001) Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res 61(19):7039-7043 (Pubitemid 32946492)
4. Ellison DW, Onilude OE, Lindsey JC et al (2005) β-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23(31):7951-7957. doi:10.1200/jco.2005.01.5479 (Pubitemid 46657395)
5. Gajjar A, Chintagumpala M, Ashley D et al (2006) Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7(10):813-820 (Pubitemid 44464063)
6. Garre ML, Cama A, Bagnasco F et al (2009) Medulloblastoma variants: age-dependent occurrence and relation to gorlin syndrome - a new clinical perspective. Clin Cancer Res 15(7):2463-2471. doi:10.1158/1078-0432.ccr-08-2023
7. Hoff KV, Hinkes B, Gerber NU et al (2009) Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT[']91. Eur J Cancer 45(7):1209-1217
8. Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Statist 6(1):65-70
9. Hovestadt V, Remke M, Kool M et al (2013) Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol 125(6):913-916
10. Jakacki RI, Burger PC, Zhou T et al (2012) Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II Study. J Clin Oncol 30(21):2648-2653. doi:10.1200/jco.2011.40.2792
11. Jones DTW, Jager N, Kool M et al (2012) Dissecting the genomic complexity underlying medulloblastoma. Nature 488(7409):100-105. doi:10.1038/nature11284
12. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53(282):457-481. doi: 10.1080/01621459.1958. 10501452
13. Koch A, Hrychyk A, Hartmann W et al (2007) Mutations of the Wnt antagonist AXIN2(Conductin) result in TCF-dependent transcription in medulloblastomas. Int J Cancer 121(2):284-291 (Pubitemid 46917696)
14. Koch A, Waha A, Tonn J et al (2001) Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer 93(3):445-449 (Pubitemid 32592067)
15. Kool M, Jones DTW, Jager N et al (2014) Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 25(3):393-405. doi:10.1016/j.ccr.2014.02.004
16. Kool M, Korshunov A, Remke M et al (2012) Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 123(4):465-472
17. Kool M, Koster J, Bunt J et al (2008) Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 3(8):e3088
18. Korshunov A, Remke M, Werft W et al (2010) Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol 28(18):3054-3060
19. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of tumours of the central nervous system. IARC Press, Lyon
20. Northcott P, Jones D, Kool M et al (2012) Medulloblastomics: the end of the beginning. Nat Rev Cancer 12(12):818-834
21. Northcott P, Korshunov A, Witt H et al (2010) Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29(11):1408-1414
22. Packer RJ, Gajjar A, Vezina G et al (2006) Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly Diagnosed average-risk medulloblastoma. J Clin Oncol 24(25):4202-4208. doi:10.1200/jco.2006.06.4980 (Pubitemid 46622300)
23. Pfaff E, Remke M, Sturm D et al (2010) TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol 28(35):5188-5196. doi:10.1200/JCO.2010.31.1670
24. Pfister S, Remke M, Benner A et al (2009) Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 27(10):1627-1636. doi:10.1200/JCO.2008. 17.9432
25. Rausch T, Jones DT, Zapatka M et al (2012) Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148(1-2):59-71. doi:10.1016/j.cell.2011.12.013
26. Remke M, Hielscher T, Northcott P et al (2011) Adult medulloblastoma is comprised of three major molecular variants. J Clin Oncol 29(19):2717-2723
27. Rutkowski S, Bode U, Deinlein F et al (2005) Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352(10):978-986. doi:10.1056/NEJMoa042176 (Pubitemid 40349500)
28. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30(12):e57. doi:10.1093/nar/gnf056
29. Schwalbe E, Williamson D, Lindsey J et al (2013) DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol 125(3):359-371. doi:10.1007/s00401-012-1077-2
30. Taylor MD, Liu L, Raffel C et al (2002) Mutations in SUFU predispose to medulloblastoma. Nat Genet 31(3):306-310
31. Taylor MD, Northcott P, Korshunov A et al (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123(4):465-472. doi:10.1007/s00401-011-0922-z
32. Thompson MC, Fuller C, Hogg TL et al (2006) Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24(12):1924-1931. doi:10.1200/jco.2005.04.4974 (Pubitemid 46638992)
33. Zhukova N, Ramaswamy V, Remke M et al (2013) Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 31(23):2927-2935. doi:10.1200/jco.2012.48.5052